International Journal of Molecular Sciences (May 2022)
The Role of T Cell Immunity in Monoclonal Gammopathy and Multiple Myeloma: From Immunopathogenesis to Novel Therapeutic Approaches
- Ivana Lagreca,
- Giovanni Riva,
- Vincenzo Nasillo,
- Patrizia Barozzi,
- Ilaria Castelli,
- Sabrina Basso,
- Francesca Bettelli,
- Davide Giusti,
- Angela Cuoghi,
- Paola Bresciani,
- Andrea Messerotti,
- Andrea Gilioli,
- Valeria Pioli,
- Corrado Colasante,
- Daniela Vallerini,
- Ambra Paolini,
- Monica Maccaferri,
- Francesca Donatelli,
- Fabio Forghieri,
- Monica Morselli,
- Elisabetta Colaci,
- Giovanna Leonardi,
- Roberto Marasca,
- Leonardo Potenza,
- Rossella Manfredini,
- Enrico Tagliafico,
- Tommaso Trenti,
- Patrizia Comoli,
- Mario Luppi
Affiliations
- Ivana Lagreca
- Section of Hematology, Department of Surgical and Medical Sciences, University of Modena and Reggio Emilia, AOU Modena, 41124 Modena, Italy
- Giovanni Riva
- Diagnostic Hematology and Clinical Genomics, Department of Laboratory Medicine and Pathology, AUSL/AOU Modena, 41124 Modena, Italy
- Vincenzo Nasillo
- Diagnostic Hematology and Clinical Genomics, Department of Laboratory Medicine and Pathology, AUSL/AOU Modena, 41124 Modena, Italy
- Patrizia Barozzi
- Section of Hematology, Department of Surgical and Medical Sciences, University of Modena and Reggio Emilia, AOU Modena, 41124 Modena, Italy
- Ilaria Castelli
- Section of Hematology, Department of Surgical and Medical Sciences, University of Modena and Reggio Emilia, AOU Modena, 41124 Modena, Italy
- Sabrina Basso
- Pediatric Hematology/Oncology Unit and Cell Factory, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, 27100 Pavia, Italy
- Francesca Bettelli
- Section of Hematology, Department of Surgical and Medical Sciences, University of Modena and Reggio Emilia, AOU Modena, 41124 Modena, Italy
- Davide Giusti
- Section of Hematology, Department of Surgical and Medical Sciences, University of Modena and Reggio Emilia, AOU Modena, 41124 Modena, Italy
- Angela Cuoghi
- Section of Hematology, Department of Surgical and Medical Sciences, University of Modena and Reggio Emilia, AOU Modena, 41124 Modena, Italy
- Paola Bresciani
- Section of Hematology, Department of Surgical and Medical Sciences, University of Modena and Reggio Emilia, AOU Modena, 41124 Modena, Italy
- Andrea Messerotti
- Section of Hematology, Department of Surgical and Medical Sciences, University of Modena and Reggio Emilia, AOU Modena, 41124 Modena, Italy
- Andrea Gilioli
- Section of Hematology, Department of Surgical and Medical Sciences, University of Modena and Reggio Emilia, AOU Modena, 41124 Modena, Italy
- Valeria Pioli
- Section of Hematology, Department of Surgical and Medical Sciences, University of Modena and Reggio Emilia, AOU Modena, 41124 Modena, Italy
- Corrado Colasante
- Section of Hematology, Department of Surgical and Medical Sciences, University of Modena and Reggio Emilia, AOU Modena, 41124 Modena, Italy
- Daniela Vallerini
- Section of Hematology, Department of Surgical and Medical Sciences, University of Modena and Reggio Emilia, AOU Modena, 41124 Modena, Italy
- Ambra Paolini
- Section of Hematology, Department of Surgical and Medical Sciences, University of Modena and Reggio Emilia, AOU Modena, 41124 Modena, Italy
- Monica Maccaferri
- Section of Hematology, Department of Surgical and Medical Sciences, University of Modena and Reggio Emilia, AOU Modena, 41124 Modena, Italy
- Francesca Donatelli
- Section of Hematology, Department of Surgical and Medical Sciences, University of Modena and Reggio Emilia, AOU Modena, 41124 Modena, Italy
- Fabio Forghieri
- Section of Hematology, Department of Surgical and Medical Sciences, University of Modena and Reggio Emilia, AOU Modena, 41124 Modena, Italy
- Monica Morselli
- Section of Hematology, Department of Surgical and Medical Sciences, University of Modena and Reggio Emilia, AOU Modena, 41124 Modena, Italy
- Elisabetta Colaci
- Section of Hematology, Department of Surgical and Medical Sciences, University of Modena and Reggio Emilia, AOU Modena, 41124 Modena, Italy
- Giovanna Leonardi
- Section of Hematology, Department of Surgical and Medical Sciences, University of Modena and Reggio Emilia, AOU Modena, 41124 Modena, Italy
- Roberto Marasca
- Section of Hematology, Department of Surgical and Medical Sciences, University of Modena and Reggio Emilia, AOU Modena, 41124 Modena, Italy
- Leonardo Potenza
- Section of Hematology, Department of Surgical and Medical Sciences, University of Modena and Reggio Emilia, AOU Modena, 41124 Modena, Italy
- Rossella Manfredini
- Centre for Regenerative Medicine “S. Ferrari”, University of Modena and Reggio Emilia, 41125 Modena, Italy
- Enrico Tagliafico
- Diagnostic Hematology and Clinical Genomics, Department of Laboratory Medicine and Pathology, AUSL/AOU Modena, 41124 Modena, Italy
- Tommaso Trenti
- Diagnostic Hematology and Clinical Genomics, Department of Laboratory Medicine and Pathology, AUSL/AOU Modena, 41124 Modena, Italy
- Patrizia Comoli
- Pediatric Hematology/Oncology Unit and Cell Factory, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, 27100 Pavia, Italy
- Mario Luppi
- Section of Hematology, Department of Surgical and Medical Sciences, University of Modena and Reggio Emilia, AOU Modena, 41124 Modena, Italy
- DOI
- https://doi.org/10.3390/ijms23095242
- Journal volume & issue
-
Vol. 23,
no. 9
p. 5242
Abstract
Multiple Myeloma (MM) is a malignant growth of clonal plasma cells, typically arising from asymptomatic precursor conditions, namely monoclonal gammopathy of undetermined significance (MGUS) and smoldering MM (SMM). Profound immunological dysfunctions and cytokine deregulation are known to characterize the evolution of the disease, allowing immune escape and proliferation of neoplastic plasma cells. In the past decades, several studies have shown that the immune system can recognize MGUS and MM clonal cells, suggesting that anti-myeloma T cell immunity could be harnessed for therapeutic purposes. In line with this notion, chimeric antigen receptor T cell (CAR-T) therapy is emerging as a novel treatment in MM, especially in the relapsed/refractory disease setting. In this review, we focus on the pivotal contribution of T cell impairment in the immunopathogenesis of plasma cell dyscrasias and, in particular, in the disease progression from MGUS to SMM and MM, highlighting the potentials of T cell-based immunotherapeutic approaches in these settings.
Keywords